Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Background:
- Advanced cases of non-small-cell lung carcinoma (NSCLC) usually are not successfully
treated with standard therapies. Even treatments that attempt to specifically target
NSCLC cells have not proved effective.
- Researchers are interested in determining whether a combination of the chemotherapy
drugs SS1 (dsFv) PE38, paclitaxel, carboplatin, and bevacizumab may be effective in
shrinking the size of NSCLC tumors. Three of the drugs (paclitaxel, carboplatin, and
bevacizumab) are commercially available, while the other is a drug that is currently
being tested to determine its usefulness in cancer treatment. This study will help to
determine if the combination of all four drugs is more effective and as safe, safer, or
less safe than other drug combinations given to treat NSCLC.
Objectives:
- To determine a safe and tolerable dose for the combination of SS1 (dsFv) PE38 with
paclitaxel, carboplatin, and bevacizumab in patients with advanced mesothelin-expressing lung
adenocarcinoma.
Eligibility:
- Age > 18 years of age
- Newly diagnosed advanced non-small-cell lung carcinoma
- No prior chemotherapy for lung cancer
- Individuals at least 18 years of age who have advanced non-small-cell lung carcinoma
that has not responded to standard treatments.
Design:
- The study will last for two 21-day cycles of treatment for the four-drug combination,
with additional treatment cycles of carboplatin, paclitaxel, and bevacizumab.
- Two to three weeks prior to the study, participants will be screened with a full medical
history and physical exam, bone marrow biopsy (we do not do bone marrow biopsies) (if
one has not been performed in the last 6 months), computed tomography (CT) or ultrasound
scan, tumor measurements, and other tests as required by the researchers. Participants
will provide blood and urine samples at this time as well.
- During the study, participants will receive SS1 (dsFv) PE38, carboplatin, paclitaxel,
and bevacizumab for a maximum of two cycles. On Day 15 of the first cycle, participants
will provide a blood sample to be tested to see if SS1 (dsFv) PE38 is being effective.
If the tests show that SS1 (dsFv) PE38 is not effective, participants will not receive
another dose of it, but will continue to receive paclitaxel, carboplatin, and
bevacizumab for the second cycle.
- After the first two cycles, participants will continue to receive carboplatin,
paclitaxel, and bevacizumab every 3 weeks for up t...
- Treatment with platinum-based doublet chemotherapy results in a median survival of 7 to
10 months in patients with locally advanced or metastatic non-small cell lung cancer.
- In a randomized clinical trial of patients with non-squamous cell lung cancer, treatment
with carboplatin, paclitaxel and bevacizumab resulted in an objective response rate of
35%, overall survival of 12.3 months compared to objective response rate of 15%, overall
survival of 10.3 months in patients treated with carboplatin and paclitaxel alone.
- Mesothelin is a cell surface glycoprotein present on normal mesothelial cells that is
highly expressed in many human cancers including lung adenocarcinoma.
- SS1 (dsFv) PE38 is a recombinant anti-mesothelin immunotoxin that has undergone phase I
testing and is currently in clinical trials in combination with pemetrexed and cisplatin
for treatment of malignant pleural mesothelioma.
- Pre-clinical studies demonstrate increased anti-tumor activity of SS1 (dsFv) PE38 in
combination with chemotherapy and bevacizumab against mesothelin-expressing tumors.
Primary Objectives:
- This is a phase I study to determine a safe and tolerable phase II dose for the combination
of SS1 (dsFv) PE38 with paclitaxel, carboplatin and bevacizumab in patients with advanced
mesothelin-expressing lung adenocarcinoma.
Secondary Objectives:
- To assess response rate, duration of response, and progression-free survival (PFS).
- To characterize the pharmacokinetics (PK) of SS1 (dsFv) PE38 in combination with
chemotherapy and bevacizumab.
- Monitor serum mesothelin levels prior to and during chemotherapy.
- To identify T-cell epitopes responsible for neutralizing SS1 (dsFv) PE38 activity using
mononuclear cells obtained by apheresis.
Eligibility:
- Histologically confirmed stage IIIB (malignant pleural effusion) or IV or recurrent
NSCLC (non-squamous cell, with mesothelin expression greater than or equal to 10% of
tumor cells by IHC).
- Adequate organ and bone marrow function.
- ECOG performance status of 0-1.
Design:
- Open label phase I trial.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |